David L. Elion - Concepedia

Author

David L. Elion

Vanderbilt University

Also Known As

David Elion, David L. Elion

Publications

557

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Vanderbilt University Medical Center

About

David L. Elion is an author at Vanderbilt University specializing in gene expression, chromatin, and transcription factors.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	33
2	Cell Biology	1	1	33
3	Epigenetics	1	1	33
4	Gene Expression	1	1	33
5	Genetics	1	1	33

David L. Elion

Publications

450

Citations

H-Index

Page 1

	Year	Citations
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers David L. Elion, Max E. Jacobson, Donna J. Hicks, Cancer Research	2018	175
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1 Thomas A. Werfel, David L. Elion, Bushra Rahman, Cancer Research	2018	86
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Michelle M. Williams, Linus Lee, Donna J. Hicks, Molecular Cancer Research	2016	53
Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler Chase M. Woodley, Alexander S. Romer, Jing Wang, Oncogene ChromatinChromatin RemodelingMultiple InteractionsGeneticsGene Regulation	2021	33
ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation Michelle M. Williams, David Vaught, Meghan M. Joly, Breast Cancer Research	2017	26
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers Michelle M. Williams, David L. Elion, Bushra Rahman, Oncotarget	2019	24
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers Michelle M. Williams, Linus Lee, Thomas A. Werfel, Cell Death and Disease	2018	23
Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Thomas A. Werfel, Donna J. Hicks, Bushra Rahman, Molecular Cancer Therapeutics	2020	19
MLL3 is a <i>de novo</i> cause of endocrine therapy resistance Kimberly M. Stauffer, David L. Elion, Rebecca S. Cook, Cancer Medicine	2021	11

Page 1